Eagle Pharmaceuticals, Inc. - EGRX EV/Sales Multiple

Public company logo of Eagle Pharmaceuticals (EGRX)

Risks for Eagle Pharmaceuticals (EGRX) are linked to a limited portfolio and generic pressure. Comparing the Enterprise Value to Sales ratio on GURU.Markets, we see that this metric equals . Rising patent costs are constraining margin scaling, yet the company is expanding its patient reach in the US, leveraging oncology and critical care medications.

Enterprise Value-to-Revenue Ratio: eagleus.com (EGRX) for 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Eagle Pharmaceuticals, Inc. (EGRX)

- price and consensus price forecast:
- money and cash flow information:
Initial company analysis:Eagle Pharmaceuticals Inc.
Core merchandise of eagleus.com

Against a backdrop of cost optimization and stable cash flow from approved drugs, the EV/Sales multiple chart visualizes the market value of Eagle Pharmaceuticals (EGRX) inclusive of net debt. This indicator compares the total enterprise value with revenue, allowing investors to assess the efficiency of asset monetization and determine the extent of overpayment for the company relative to its operational scale.